Foghorn Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.9 | $22.6 | $34.2 | $19.2 | $1.3 |
| Operating income | -$86.4 | -$102.7 | -$107.9 | -$117.1 | -$100.7 |
| Net income | -$74.3 | -$86.6 | -$98.4 | -$108.9 | -$101.3 |
| Cash Flow Statement | |||||
| Free cash flow | -$86.1 | -$101.3 | -$119.3 | $192.4 | -$53.6 |
Shares outstanding 59.4M · Free float 68.0%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.